Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.
Rhythm Biosciences has announced peer‑reviewed publication of clinical validation data for its first-generation ColoSTAT singleplex blood test for colorectal cancer, showing 81.3% sensitivity and 91% specificity in a 989‑patient, multi-centre study, with performance comparable to stool-based tests used in Australia’s national bowel cancer screening program. The results underpin a near-term commercial push into the large symptomatic patient triage market, where ColoSTAT could help prioritise up to 800,000 annual colonoscopy referrals in Australia by distinguishing cancer from benign gastrointestinal conditions, potentially halving unnecessary procedures and related costs, and supporting future regulatory approvals and partnership discussions for the optimised second-generation multiplex test.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian-based predictive cancer diagnostics technology company focused on developing blood-based tests for colorectal cancer. Its lead product, ColoSTAT, targets the colorectal cancer diagnostics market, particularly symptomatic patients who would otherwise undergo invasive and costly colonoscopy procedures, with a view to improving patient compliance and health system efficiency.
Average Trading Volume: 513,499
Technical Sentiment Signal: Buy
Current Market Cap: A$53.96M
See more data about RHY stock on TipRanks’ Stock Analysis page.